Akeso Inc (9926)

Currency in HKD
160.40
+3.00(+1.91%)
Closed·
9926 Scorecard
Full Analysis
Net income is expected to grow this year
9926 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
154.50161.60
52 wk Range
42.80173.20
Key Statistics
Bid/Ask
160.30 / 160.40
Prev. Close
157.4
Open
157.3
Day's Range
154.5-161.6
52 wk Range
42.8-173.2
Volume
9.48M
Average Volume (3m)
12.78M
1-Year Change
264.96%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
9926 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
122.24
Downside
-23.79%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Akeso Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Akeso Inc Company Profile

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, and recurrent or refractory classical Hodgkin lymphoma; AK109, a PD-1 monoclonal antibody to treat G/GEJ patients; penpulimab, a PD-1 for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC); and tagitanlimab, a PD-L1 for treating recurrent or metastatic NPC. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK120 to treat moderate-to-severe atopic dermatitis. The company was founded in 2012 and is headquartered in Zhongshan, the People’s Republic of China.

Compare 9926 to Peers and Sector

Metrics to compare
9926
Peers
Sector
Relationship
P/E Ratio
−254.2x−11.9x−0.5x
PEG Ratio
2.050.300.00
Price/Book
19.2x7.1x2.6x
Price / LTM Sales
61.6x16.9x3.3x
Upside (Analyst Target)
−27.9%−12.1%43.5%
Fair Value Upside
Unlock−16.3%6.8%Unlock

Analyst Ratings

22 Buy
1 Hold
0 Sell
Ratings:
23 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 122.24
(-23.79% Downside)

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
-0.32 / --
Revenue / Forecast
1.10B / --
EPS Revisions
Last 90 days

9926 Income Statement

People Also Watch

91.25
1801
-0.16%
278.00
9992
-0.29%
10.26
1093
+5.99%
120.80
3690
-0.98%
48.66
0981
-8.19%

FAQ

What Stock Exchange Does Akeso Trade On?

Akeso is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for Akeso?

The stock symbol for Akeso is "9926."

What Is the Akeso Market Cap?

As of today, Akeso market cap is 143.97B.

What Is Akeso's Earnings Per Share (TTM)?

The Akeso EPS (TTM) is -0.60.

From a Technical Analysis Perspective, Is 9926 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Akeso Stock Split?

Akeso has split 0 times.

How Many Employees Does Akeso Have?

Akeso has 3035 employees.

What is the current trading status of Akeso (9926)?

As of 09 Aug 2025, Akeso (9926) is trading at a price of 160.40, with a previous close of 157.40. The stock has fluctuated within a day range of 154.50 to 161.60, while its 52-week range spans from 42.80 to 173.20.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.